A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

University of California San Diego

Status and phase: Suspended; Phase 2

Conditions: Insulin Resistance; Obesity

Treatments: Drug: Fenretinide; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00546455

061257

Details and patient eligibility

About

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.

Enrollment: 21 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• BMI >30

Exclusion criteria

• Diabetes Requiring Medication
• Poorly Controlled Co-Morbidities

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

21 participants in 2 patient groups, including a placebo group

A

Experimental group

Description:

Subjects in this cohort will be given Fenretinide

Treatment:

Drug: Fenretinide

B

Placebo Comparator group

Description:

Subjects in this cohort will be given placebo.

Treatment:

Drug: Placebo